The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and ...

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

OpenLoop, a company providing operational and tech services to telehealth companies, and compounding pharmacy Triad Rx are being sued in a class action for selling oral tirzepatide. | The complaint ...

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded drugs ...

Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers and other ...

On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...

Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a ...

Hims & Hers (HIMS) stock jumps as the company plans to launch cheaper compounded versions of Novo Nodisk's (NVO) Wegovy pill.

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies ...